Research from the University of Colorado Cancer Center member Terry Fry, MD, reveals how CAR-T cells' antigen history influences cancer-fighting effectiveness and durability. The study highlights potential genetic targets to optimize CAR-T cell engineering, improving precision and reducing side effects.